[DEBUG-WINDOW 처리영역 보기]
즐겨찾기  |  뉴스레터  |  오늘의 정보  |  e브릭몰e브릭몰 회원가입   로그인
BRIC홈 한국을 빛내는 사람들
2019 Bio Top5 인터뷰
스폰서배너광고 안내  배너1
전체보기 추천논문 상위피인용논문 인터뷰 그이후 한빛사통계
최종기
최종기 (Jonggi Choi) 저자 이메일 보기
울산대학교 의과대학, 서울아산병원
 
조회 62  인쇄하기 주소복사 트위터 공유 페이스북 공유 
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B A Korean Nationwide Cohort Study
열기 Authors and Affiliations

Abstract

Importance 
Entecavir and tenofovir disoproxil fumarate have comparable efficacy in achieving surrogate end points, including virologic response, and are equally recommended as first-line treatments for patients with chronic hepatitis B (CHB). However, it is unclear whether treatment with these drugs is associated with equivalent clinical outcomes, especially development of hepatocellular carcinoma (HCC).

Objective
To compare entecavir and tenofovir in terms of the risk of HCC and death or liver transplant in patients with CHB infection.

Design, Setting, and Participants 
A nationwide historical population cohort study involving treatment-naive adult patients with CHB who started treatment with entecavir (n = 11 464) or tenofovir disoproxil fumarate (n = 12 692) between January 1, 2012, and December 31, 2014, using data from the Korean National Health Insurance Service database. As validation, a hospital cohort of patients with CHB treated with entecavir (n = 1560) or tenofovir (n = 1141) in a tertiary referral center between January 1, 2010, and December 31, 2016, were analyzed. Nationwide cohort data were retrieved from January 1, 2010, to December 31, 2016, and hospital cohort data from January 1, 2010, to October 31, 2017.

Main Outcomes and Measures 
Cumulative incidence rates of HCC and death and transplant rates.

Results
Among the population cohort of 24 156, the mean (SD) age was 48.9 (9.8) years, and 15 120 patients (62.6%) were male. Among the hospital cohort of 2701, the mean (SD) age was 48.8 (10.5) years and 1657 patients (61.3%) were male. In the population cohort, the annual incidence rate of HCC was significantly lower in the tenofovir group (0.89 per 100 person-years [PY]) than in the entecavir group (1.19 per 100 PY). By multivariable-adjusted analysis, tenofovir therapy was associated with a significantly lower risk of HCC (hazard ratio [HR], 0.68; 95% CI, 0.59-0.77) and no significantly different risk of all-cause mortality or transplant (HR, 0.89; 95% CI, 0.73-1.07) compared with entecavir. The tenofovir group also showed a significantly lower risk of HCC in the 10 923-pair propensity score–matched population cohort (HR, 0.68; 95% CI, 0.60-0.78) and 869-pair propensity score–matched hospital cohort (HR, 0.68; 95% CI, 0.46-0.99) compared with the entecavir group.

Conclusions and Relevance 
This study suggests that tenofovir treatment was associated with a significantly lower risk of HCC compared with entecavir treatment in a population-based cohort of adults with CHB, but there was no statistically significant difference in mortality. These findings were validated in a hospital cohort. Given the poor prognosis of patients with HCC, these findings may have considerable clinical implications in prevention of this cancer in patients with CHB infection.

논문정보
- 형식: Research article
- 게재일: 2019년 01월 (BRIC 등록일 2019-01-21)
- 연구진: 국내연구진태극기
- 분야: Medicine, Cancer Biology/Oncology
경제적 의사결정의 개별과정을 동질한 성격의 뉴런으로 구현하기[Neuron]
유승범
발표: 유승범 (University of Minnesota)
일자: 2020년 1월 29일 (수) 오전 10시 (한국시간)
언어: 영어
참석자 접수신청하기
유전자 편집 기술을 활용한 도시농업 적합 작물 개발[Nat. Biotechnol.]
권춘탁
발표: 권춘탁 (Cold Spring Harbor Labor...)
일자: 2020년 2월 19일 (수) 오전 11시 (한국시간)
언어: 한국어
참석자 접수신청하기

  댓글 0
등록
 
목록
데일리파트너스
관련링크
최종기 님 전체논문보기 >
관련인물
고민정 (한국보건의료연구원)
김남국 (울산의대/아산병원)
김효정 (한국보건의료연구원)
임영석 (울산대학교 의과대학)
관련분야 논문보기
Medicine

Cancer Biology/Oncology

외부링크
Google (by Jonggi Choi)
Pubmed (by Jonggi Choi)
프리미엄 Bio일정 Bio일정 프리미엄 안내
[BRIC Webinar]경제적 의사결정의 개별과정을 동질한 성격의 뉴런으로 구현하기[Neuron]
[BRIC Webinar]Overview of NGS library Preparation[필코리아테크놀로지]
[BRIC Webinar]Overview of NGS library Preparation[필코리아테크놀로지]
사전접수: ~2020.01.21
날짜: 2020.01.22
Online 개최
제33차 연세 비부비동 심포지엄 "Recent Advances in Olfaction and Gustation"
제33차 연세 비부비동 심포지엄 "Recent Advances in Olfaction and Gustation"
사전접수: ~2020.01.10
날짜: 2020.01.19
장소: 신촌 연세의료원 에비슨의생명연구센터(ABMRC) 1층 유일한 홀
[무료/ 취업연계]바이오QC 실무과정 8기 모집
[무료/ 취업연계]바이오QC 실무과정 8기 모집
사전접수: ~2020.02.10
날짜: 2020.03.02~06.12
장소: 성남시 분당구 황새울로
위로가기
한빛사 홈  |  한빛사FAQ  |  한빛사 문의 및 제안
 |  BRIC소개  |  이용안내  |  이용약관  |  개인정보처리방침  |  이메일무단수집거부
Copyright © BRIC. All rights reserved.  |  문의 member@ibric.org
트위터 트위터    페이스북 페이스북   유튜브 유튜브    RSS서비스 RSS
라이카코리아